drugset / Trial / NCT00348348
A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a study to investigate a novel drug candidate for the treatment of bacterial conjunctivitis.
Timeline
- Start
- 2006-06
- Primary completion
- 2007-07
- Completion
- 2007-07
Publications
- DeCory HH, Sanfilippo CM, Proskin HM, Blondeau JM. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6. PLoS One. 2020 Aug 25;15(8):e0237603. doi: 10.1371/journal.pone.0237603. eCollection 2020.
- Comstock TL, Paterno MR, Decory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Investig. 2010;30(10):675-85. doi: 10.2165/11536720-000000000-00000.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Besifloxacin | Small molecule | 0.6 % | Other |
| Comparator | Moxifloxacin | Small molecule | 0.5 % | Other |